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Background: Although advances in sequencing technologies have popularized the use of microRNA (miRNA)
sequencing (miRNA-seq) for the quantification of miRNA expression, questions remain concerning the optimal
methodologies for analysis and utilization of the data. The construction of a miRNA sequencing library selects RNA
by length rather than type. However, as we have previously described, miRNAs represent only a subset of the
species obtained by size selection. Consequently, the libraries obtained for miRNA sequencing also contain a variety
of additional species of small RNAs. This study looks at the prevalence of these other species obtained from bone
marrow aspirate specimens and explores the predictive value of these small RNAs in the determination of response
to therapy in myelodysplastic syndromes (MDS).
Methods: Paired pre and post treatment bone marrow aspirate specimens were obtained from patients with MDS
who were treated with either azacytidine or decitabine (24 pre-treatment specimens, 23 post-treatment specimens)
with 22 additional non-MDS control specimens. Total RNA was extracted from these specimens and submitted for next
generation sequencing after an additional size exclusion step to enrich for small RNAs. The species of small RNAs were
enumerated, single nucleotide variants (SNVs) identified, and finally the differential expression of tRNA-derived species
(tDRs) in the specimens correlated with diseasestatus and response to therapy.
Results: Using miRNA sequencing data generated from bone marrow aspirate samples of patients with known MDS
(N = 47) and controls (N = 23), we demonstrated that transfer RNA (tRNA) fragments (specifically tRNA halves, tRHs) are
one of the most common species of small RNA isolated from size selection. Using tRNA expression values extracted
from miRNA sequencing data, we identified six tRNA fragments that are differentially expressed between MDS and
normal samples. Using the elastic net method, we identified four tRNAs-derived small RNAs (tDRs) that together can
explain 67 % of the variation in treatment response for MDS patients. Similar analysis of specifically mitochondrial tDRs
(mt-tDRs) identified 13 mt-tDRs which distinguished disease status in the samples and a single mt-tDR which predited
response. Finally, 14 SNVs within the tDRs were found in at least 20 % of the MDS samples and were not observed in
any of the control specimens.
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Discussion: This study highlights the prevalence of tDRs in RNA-seq studies focused on small RNAs. The potential
etiologies of these species, both technical and biologic, are discussed as well as important challenges in the
interpretation of tDR data.
Conclusions: Our analysis results suggest that tRNA fragments can be accurately detected through miRNA sequencing
data and that the expression of these species may be useful in the diagnosis of MDS and the prediction of response to
therapy.
Keyword: Transfer RNA (tRNA), microRNA (miRNA), Next generation (deep) sequencing (NGS), Predictive biomarkers,
DNA methyltransferase inhibitor, Response to therapy, Myelodysplastic syndromes (MDS)Background
RNA next generation sequencing (RNA-seq) technology
has replaced microarrays as the primary platform for gene
expression profiling [1–4]. This same technology has also
been used to study the expression of microRNAs (miR-
NAs), although there are fewer direct comparisons
between miRNA arrays and miRNA-seq [5–7]. During
miRNA-seq library preparation, small RNAs are selected
by electrophoresis on a size typically ranging from 20 to
50 nucleotides (nts). This range of size selection allows for
the capture of many other species of small RNAs in
addition to miRNAs [8–15].
One of the major byproducts of size selection for miR-
NAs is tRNA-derived small RNAs (tDRs) [13, 16]. This
may be the result of either active cleavage or an artifact of
the miRNA-seq library construction. Full length or parent
tRNAs are adaptor molecules composed of RNA with a
length typically ranging from 73 to 94 nts. They serve as
the physical link that translates messenger RNA into
protein. Cleavage of tRNAs by the RNAse III enzyme,
angiogenin, may occur in a number of reactive conditions
to produce tRNA-derived halves (tRHs) [17, 18]. Likewise,
tRNAs can also be cleaved in a Dicer-dependent manner
or as an in vitro phenomenon by incubation with MgCl2
or nuclease S1 [10, 19]. All of these processes result in
cleavage within a hairpin loop. D loop cleavage results in a
19 nt tRNA-derived fragment (tRF), and cleavage of the
anticodon loop before the anti-codon affords a 33 nt tRH
[10, 19]. These 5’ tDR products, in particular the 33-base
tRH, may be captured by miRNA-seq.
In addition, apparent tDRs and tRNAs with base errors
found in RNA-seq datasets may arise from the extensive
chemical modifications of parent tRNA nucleotides. While
these modifications contribute physiologically to RNA
stability, function, and structure [20], they may be either
misincorporated during the requisite reverse transcription
step [21], resulting in specific base errors [22], or result in
blockage of reverse transcription, with production of a
truncated cDNA product [23]. Therefore, sequencing data-
sets may contain many reads that appear to be tDRs, but infact are actually derived from full-length parent tRNA
templates.
The quantification of tRNAs and tDRs warrant study
through high-throughput sequencing. Aberrations in
tRNAs have been linked to a range of diseases, including
neurological disorders [24–26], cancer [27–29], type II
diabetes [30–32], and mitochondrial diseases [33–35]. In
addition, tDRs have been identified in a number of cancer
cell lines, and some tDRs may play defined biological
roles, such as the role of tRF-1001 in proliferation [11].
Thus far, only one study has found a link between som-
atic mutations in mitochondrial tRNA (Leu (UUR), aka
MT-TL1) and myelodysplastic syndromes (MDS) [36].
The potential functionality of tRNA in MDS remains
largely unexplored.
As part of our efforts to study MDS, we have previously
examined miRNA expression in MDS [37, 38]. MDS is a
common disease of the elderly (median age 71–76) [39]
characterized by ineffective maturation of hematopoietic
cells. This ineffective maturation manifests clinically as
low blood counts and morphologically as dysplasia. The
MDS state has been associated with expression changes in
miRNAs. Several entities have been discovered on 5q,
which contribute to the disease phenotype in the 5q
minus syndrome subtype of MDS [40]. miR-145 and miR-
146 have recently been identified in the commonly deleted
region, and their knockdown appears to be associated with
the thrombocytosis and dysmegakaryopoiesis seen in 5q
minus syndrome [41]. Researchers, including those in our
group, have identified several other miRNAs whose ex-
pression is dysregulated with the diagnosis of other sub-
types of MDS [37, 38, 42–45]. Published research on other
types of small RNAs in MDS is limited.
MDS has a median survival of only 18–24 months [46],
with death resulting from either cytopenic complications
or transformation to acute myeloid leukemia (AML) [47].
Currently, there are only two FDA-approved drugs for the
treatment of all types of MDS, both of which are DNA
methyltransferase inhibitors (DNMTIs): 5-azacytidine,
and decitabine. However, only 40–47 % of patients achieve
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provement or better with DNMTIs [48]. Although several
recent studies have suggested the use of mutational ana-
lysis by DNA next generation sequencing (NGS, DNA-
seq) [49], genetics [50], or the presence or absence of key
pharmacodynamic and pharmacokinetic markers [51] to
predict response, as yet, there are no clinical or laboratory
parameters in routine clinical practice that accurately
predict response to DNMTIs [52–54]. The methylation
status of specific loci has been shown to be prognostically
relevant in the treatment of a closely related disease,
chronic myelomonocytic leukemia, by decitabine [55].
In this study, we examined the expression of tRNAs in
paired pre- and post-treatment samples from patients with
the diagnosis of MDS on receiving treatment with
DNMTIs. In miRNA sequencing data, the abundance of
tRNA fragments vastly outnumbers miRNAs. This gives us
a great opportunity to study tRNA expression using miRNA
sequencing data through their anticodon sequences.
Methods
Ethics statement
This study was conducted in accordance with the Declar-
ation of Helsinki with the approval of the Institutional Re-
view Boards at Roswell Park Cancer Institute and
Vanderbilt University Medical Center.
Consent statement
Written informed consent for the patient-derived speci-
mens was obtained prior to the acquisition in all cases. The
consents were approved by the Institutional Review Boards
at Roswell Park Cancer Institute and Vanderbilt University
Medical Center.
Specimen description
Bone marrow aspirate specimens (N = 69) (see Additional
file 1: Table S1) were obtained from the Roswell Park
Cancer Institute with appropriate approval by the In-
stitutional Review Boards at Roswell Park and Vanderbilt
University Medical Center. Twenty-two of the 69 bone
marrow samples were from control patients (staging
marrows that were negative for hematolymphoid malig-
nancy). The other 47 samples were from MDS patients.
Out of 47 MDS samples, 24 were pre-treatment speci-
mens, and 23 were obtained after treatment with 5-
azacytidine or decitabine, both DNMTIs. For each of the
pre- and post-treatment paired samples, a response score
(range: 1–6, where 1 represents complete remission, 2
complete marrow remission, 3 partial remission, 4
hematologic improvement, 5 stable disease, and 6 progres-
sive disease) was obtained based on clinical and patho-
logical criteria to indicate the effectiveness of treatment
(Additional file 1: Table S1) [56]. Bone marrow mono-
nuclear cells (BM-MNCs) were isolated from fresh,unsorted bone marrow aspirate specimens (N = 69) by the
Ficoll method using Cellgro Lymphocyte Separation
Medium (Corning, Manassas, VA). After performing a cell
count, the cells were re-pelleted from Dulbecco’s phos-
phate buffered saline solution and resuspended in Gibco
Recovery Freezing medium (Invitrogen, Grand Island,
NY), and then frozen gradually, prior to storage in liquid
nitrogen. Cells were frozen at a density of 10 to 20 million
cells per mL.
RNA isolation and RNA sequencing
Total RNA (totRNA) was isolated using a mirVana
miRNA isolation kit (Life Technologies, Grand Island,
NY) per manufacturer’s instructions. Sequencing library
construction was performed on the totRNA from all 69
samples, each obtained from a single bone marrow as-
pirate specimen. RNAs were isolated by the mirVana
RNA isolation kit, which was found to perform better
than the TRIzol miRNA isolation kit [13]. Libraries were
prepared using the TruSeq Small RNA sample prepar-
ation kit (Illumina, San Diego, CA). The small RNA
protocol specifically ligates RNA adapters to mature
miRNAs that have a 5’-phosphate and 3’-hydroxyl group
resulting from enzymatic cleavage by RNA processing
enzymes like Dicer. In the first step, RNA adapters were
ligated onto each end of the RNA molecules, and a
reverse transcription reaction was used to create single-
stranded cDNA. This cDNA was then PCR amplified
with a universal primer and a second primer containing
one of 48 uniquely indexed tags to allow multiplexing.
Size selection of the cDNA constructs was performed
using a 3 % gel cassette on the Pippin Prep (Sage
Sciences, Beverly, MA) to reduce the library to mature
miRNAs and other regulatory RNAs in the 20–30 bp
size range and to remove adapter-adapter products. The
resulting cDNA libraries then underwent a quality check
on the Bioanalyzer HS DNA assay (Agilent, Santa Clara,
CA) to confirm the final library size and on the Agilent
Mx3005P quantitative PCR machine using the KAPA
library quantification kit (Illumina, San Diego, CA) to
determine concentration. A 2 nM stock was created, and
samples were pooled by molarity for multiplexing. From
the pool, 10 pM was loaded into each well for the flow
cell on the Illumina cBot for cluster generation. The flow
cell was then loaded onto the Illumina HiSeq 2500 util-
izing v3 chemistry and HTA 1.8. The raw sequencing
reads in BCL format were processed through CASAVA-
1.8.2 for FASTQ conversion and demultiplexing. The
RTA chastity filter was used, and only the PF (pass filter)
reads were retained for further analysis.
Sequencing data analysis
We implemented a custom analysis pipeline for small
RNA sequencing data processing. We used Cutadapt
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raw data was performed using QC3 [58]. All reads with
length less than 12 were discarded. The adaptor-
trimmed reads were formatted into a non-redundant
FASTQ file where the read sequence and copy number
was recorded for each unique tag. The usable unique
reads were mapped to the whole genome using Bowtie1
[59] with only one mismatch allowed. The latest Sanger
microRNA database, miRBase20 [60], was used to quan-
tify microRNA isomiRs by reads mapped with position
0, +1, and +2 from the 3’ terminal of the miRBase locus.
The tRNA database was prepared by combining the
latest UCSC tRNA database with the tRNA loci of mito-
chondria from the ensembl database [61]. The reads
mapped with tRNA loci were used not only for tRNA
quantification, but also for tRNA mapping position cover-
age analysis. The reads mapped to miRNAs, tRNAs,
and other small RNAs (including lincRNAs, snoRNAs,
snRNAs, rRNAs, and misc_RNAs in the ensembl
database) were used for response category analysis. In
addition, single nucleotide variations (SNVs) can also
be detected through RNA-seq methods [14, 62–64].
We identified SNVs in the tRNA reads using VarScan
2 [65] and filtered the SNVs based on the VarScan 2
recommended filters. Inconsistent SNVs between
paired samples were removed from analysis. Only
SNVs with zero appearance in control samples were
included in the analysis.
Response analysis
A linear regression model was fit using response scores as
outcomes and tRNA expression as predictors. Differential
expression between MDS biopsy samples and controlFig. 1 Read count and alignment distribution example taken from one sam
not just unique reads per category. The other samples in this study follow
The smaller peak at 22 base pairs indicates the abundance of miRNA and t
tRNA. b. The reads alignment distribution by RNA type. The majority of thesamples were conducted using MultiRankSeq [66], which
is based on the combination of results from three distinct
RNA-seq analysis packages: DESeq [67], edgeR [68], and
baySeq [69]. A tRNA was considered significantly differen-
tially expressed if the adjusted p-values for all three
analysis packages were less than 0.05. The elastic net
method [70] was used to select a panel of tRNAs that
together explain a large proportion of the variation in
patient response. Elastic net regularization [71] is a tech-
nique that conbines the L1 and L2 penalties of the lasso
and ridge regression methods. The elastic net method
provides variable selection to produce parsimonious and
interpretable models in the p > >N case without being
severely limited by the sample size. This method greatly
improves performance in the case of highly correlated
predictor variables (as we expect to have in clinical data),
through the identification of groups of phenotypes with
significantly high correlation that contribute the most to
the variation in the data. Unsupervised hierarchical cluster
analysis was conducted using HeatMap3 [72]. Functional
analysis of tRNAs/tDRs was carried out manually by
searching online due to the lack of a functional database
for tRNA. In addition, a Fisher’s exact test was used to
identify SNVs associated with MDS.
Results
We found that for the reads obtained using a standard
miRNA-seq protocol, the number of reads aligned to tDRs
(78.81 % of reads) vastly outnumbered those aligning to
miRNAs (4.43 % of reads) (Fig. 1a). The read length distri-
bution, after trimming the adaptor with Cutadapt [57],
shows a strong modal peak at 33 nucleotides, with the
expected 22 nucleotide mean length of miRNAs (Fig. 1b)ple. The figures were produced using all read counts per category,
a similar pattern. a. Read count distribution after trimming adaptors.
he larger peak at 33 base pairs indicates the abundance primarily of
reads aligned to tRNA instead of miRNA












chrM.tRNA10-TC 1.2840 0.0006 2.5347 0.0005 0.0011
chr12.tRNA8-AlaTGC 0.8518 0.0034 1.9498 0.0005 0.0378
chr16.tRNA4-ProAGG 0.8072 0.0274 1.6531 0.0043 0.0089
chr1.tRNA58-LeuCAA −1.0706 0.0000 −0.7228 0.0406 0.0000
chr19.tRNA8-SeC(e)TCA −0.6461 0.0103 −0.5944 0.0289 0.0126
chr19.tRNA4-ThrAGT −0.8098 0.0067 −0.7906 0.0403 0.0489
alog2FC = log 2 fold change
bpAdj = adjusted p -value
cDESeq2, edgeR, and baySeq are the three RNAseq differential expression
analysis packages used in this analysis. BaySeq does not generate fold change,
thus no fold change from baySeq can be reported
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The peak at 33 bases indicates the abundance of tRNA
species that have been cleaved in the anticodon loop from
their full length of 73–94 nucleotides [10, 19]. The
complete sequenced position of each tRNA is provided in
Additional file 2: Figure S1. Numerous small RNA
mapping statistics can be located in (Additional file 1:
Table S2) (Fig. 1b).
Using MultiRankSeq, we identified six tDRs that are sig-
nificantly differentially expressed between MDS samples
and control samples (Table 1, Fig. 2). Three tDRs demon-
strated increased expression in MDS (chrM.tRNA10.TC,
chr12.tRNA8.AlaTGC, and chr16.tRNA4.ProAGG) whileFig. 2 a. Cluster analysis and heatmap using tRNA expression of all sample
treatment, post-treatment and normal controls. Two clusters are visible (lig
post-treatment, but distinguish MDS and normal samples reasonably well.three were decreased (chr1.tRNA58-LeuCAA, chr19.tR
NA8-SeC(e)TCA (SeC(e)TCA), and chr19.tRNA4-ThrA
GT). The complete results can be viewed in Additional
file 1: Table S3. Unsupervised cluster analysis showed that
tRNA profiling was able to distinguish between MDS and
control samples (χ2 p < 0.0001). No tDRs were signifi-
cantly differentially expressed between pre- and post-
treatment samples (Additional file 1: Table S4, Fig. 2).
Using the elastic net with ten-fold cross-validation
(CV) for selecting the model with the smallest CV error,
we identified a panel of four tRNA fragments (chr6.tRN
A157.ValCAC, chr11.tRNA17.ValTAC, chrM.tRNA12.TS1,
and chrX.tRNA4.ValTAC) whose combined expression in
the pre-treatment samples together are predictive of the
likelihood of response. By fitting a multivariable linear re-
gression model using expression values of these four tDRs,
two out of the four tRNA species showed significant
associations with response (chr6.tRNA157.ValCAC p =
0.03564 and chrM.tRNA12.TS1 p = 0.01362) adjusted for
other variables in the model. Overall, the model explained
roughly 67 % of the variation in treatment response (R2 =
0.6735) (Table 2). It should be noted that the first 33 nu-
cleotides of chr11.tRNA17.ValTAC and chrX.tRNA4.Val
TAC show perfect sequence homology, so these different
tRNAs cannot be distinguished by these methods. There-
fore, it is possible that one or the other species are predict-
ive of response rather than both.
Using the change of tDR expression between pre- and
post-treatment (computed as percentage of change), wes. Three phenotype bars are drawn below the dendrogram: pre-
ht green and light red). These two clusters do not separate pre- and
b. The six differentially expressed tRNA between disease and normal
Table 2 Linear regression results on tRNAs and treatment
association













Notice that not all tRNA are significant in this table; however, acting together,
they explain the greatest amount of variation in treatment
aEffect is explained as per 1 unit increase in tRNA expression; the treatment
changes the effect amount of unit
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(chr1.tRNA35.GlyGCC, chr21.tRNA2.GlyGCC, and chr1
9.tRNA9.PseudoTTT) were identified as predictors for
treatment response. Multivariate linear regression was fit
using treatment response as the outcome and tDR expres-
sion changes in the three tDRs as predictors. PseudoTTTTable 3 Test statistics of previously identified mitochondria tRNAs w
Differential ex
vs control
tRNA Association pAdj (DESeq2
MT-TF MELAS, MT-TF-related, MERRF syndrome [88] 0.0103
MT-TV Leigh syndrome, NARP, mitochondrial disorder [89] 0.0103
MT-TL1 myelodysplastic syndrome [39] 0.0299
MT-TI hypertrophic cardiomyopathy [90] 0.0431
MT-TQ MELAS [91] 0.4745
MT-TM mitochondria disorder, hypertension [92] NA
MT-TW neonatal onset mito disease [93] 0.0271
MT-TA hearing loss [94] 0.0062
MT-TN Ophthalmoplegia [95] 0.0134
MT-TC hearing loss [96] 0.0006
MT-TY mitochondrial cytopathy [97] 0.5648
MT-TS1 hearing loss [98] 0.0017
MT-TD mitochondrial myopathy [99] NA
MT-TK MELAS [100] 0.6851
MT-TG hypertrophic cardiomyopathy [101] 0.0775
MT-TR mitochondria myopathy [102] 0.4745
MT-TH MELAS [103] 0.1634
MT-TS2 mitochondrial myopathy [104] 0.0431
MT-TL2 ophthalmoplegia [105] 0.3483
MT-TE myopathy [106] 0.0271
MT-TT multiple sclerosis [107] 0.3483
MT-TP mitochondrial catopathy [108] 0.0034trended towards an association with treatment response
(p = 0.0507). Roughly 40 % of the variation in patient re-
sponses can be explained using the difference of expres-
sion between pre- and post-treatment of these three tDRs
(R-squared = 0.4056) (Table 2). It should be noted that the
first 33 nucleotides of chr1.tRNA35.GlyGCC and chr21
.tRNA2. GlyGCC are also homologous, leading to align-
ment ambiguity.
Functional correlation of tRNA expression is challen-
ging due to the dearth of available public resources fo-
cused on tRNAs. We focused on mitochondrial tRNAs
(mt-tRNAs) as a limited subset of tRNA species to study,
in particular those mt-tRNAs that have a demonstrated
disease association in the literature (see references listed
in Table 3). In Table 3, we show the false discovery rate
(FDR) p-values for the ability of these tDRs from differen-
tial expression analysis methods to distinguish between
MDS and control (Table 3, columns 3–5) and their associ-
ation with treatment response (Table 3, columns 6–8) for
all 22 mt- tDRs. Thirteen of the 22 mt-tDRs had signifi-
cantly adjusted p-values from at least two of the three
methods from MultiRankSeq in the discrimination ofith disease associations
pression of tRNA MDS Linear regression association of tRNA
with response
) pAdj (edgeR) pAdj (baySeq) Effect Std err p value
0.0015 0.4869 −1.3378 3.5754 0.7129
0.0020 0.6661 −0.1755 0.2952 0.5602
0.0030 0.4143 0.7728 1.1559 0.5127
0.0044 0.7070 −1.3977 2.8147 0.6258
0.0687 0.9095 −0.1673 0.2261 0.4693
0.0354 0.6065 −0.6015 0.2818 0.0476
0.0040 0.4824 −18.3065 27.0968 0.5084
0.0015 0.2336 −33.3062 19.0142 0.0979
0.0024 0.5159 −6.6839 3.0347 0.0417
0.0005 0.0011 −0.7931 1.1525 0.5006
0.0642 0.9019 0.0994 3.1135 0.9749
0.0009 0.1043 −54.1283 17.2749 0.0061
0.1135 0.8845 −14.0023 9.2086 0.1467
0.1933 0.9098 −0.4508 0.5028 0.3825
0.0067 0.7119 0.4488 4.0525 0.9131
0.1346 0.8194 −19.9639 10.4921 0.0742
0.0251 0.8843 −0.4952 0.4202 0.2549
0.0043 0.8107 −0.0547 0.2504 0.8295
0.0534 0.9062 −1.1874 1.2812 0.3670
0.0045 0.5381 −0.3868 0.2411 0.1271
0.0466 0.8629 −9.0631 11.8617 0.4553
0.0007 0.4374 −4.2378 3.7122 0.2694
Table 4 tRNA single nucleotide variant analysis










chr13.tRNA1-PheGAA No 13 95201919 T A 0 11 4 3 0.01
chr12.tRNA11-PheGAA No 12 125412404 T A 0 16 4 6 0.01
chr6.tRNA44-SerAGA No 6 27446616 G A 0 21 5 13 0.01
chr6.tRNA46-SerAGA No 6 27463618 G A 0 21 5 13 0.01
chr6.tRNA47-SerAGA No 6 27470843 G A 0 21 5 13 0.01
chr6.tRNA50-SerAGA No 6 27500012 G A 0 21 5 13 0.01
chr6.tRNA51-SerTGA No 6 27513493 G A 0 21 5 13 0.01
chr6.tRNA5-SerAGA No 6 26327842 G A 0 21 5 14 0.02
chr6.tRNA148-SerTGA No 6 27473663 C T 0 21 5 14 0.02
chr6.tRNA147-SerAGA No 6 27509610 C T 0 21 5 14 0.02
chr17.tRNA35-SerAGA No 17 8129984 C T 0 21 5 14 0.02
chr6.tRNA172-SerTGA No 6 26312880 C T 0 21 5 15 0.02
chr7.tRNA21-CysGCA rs192094984 7 149112285 G A 0 16 3 7 0.05
chr8.tRNA11-SerAGA No 8 96281941 C T 0 21 5 17 0.05
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this subset that had significant association with treatment
response.
Through SNV analysis, we identified 14 SNVs that have
potential associations with MDS (Table 4). These 14 SNVs
were found in at least 20 % of MDS samples and were not
observed in any of the control samples. Only one out of
the 14 SNVs has been previously identified (rs192094984)
by the 1000 Genomes Project. Some of the SNVs were
identified in the same tRNA with the same anticodon but
were located at different genomic positions. It is possible
that they are the same SNV duplicated by alignment
ambiguity.
Discussion
In this study, using miRNA sequencing data generated
from 69 BM-MNC samples and a novel bioinformatics ap-
proach, we demonstrated that tDRs are a major byproduct
of miRNA sequencing, exceeding the abundance of miR-
NAs detected by this methodology by nearly 18-fold. This
finding demonstrates the difficulties inherent in studying
low-abundance RNA species by expression analysis and
emphasizes the importance of adequate filtration.
Due to the potential information embodied in the tDR
dataset and a lack of published data on the topic, we
chose to study the expression of tDRs in MDS. We dem-
onstrated that six tDRs are differentially found in MDS
and control samples, and that a pattern of tRNA species
could be used to differentiate MDS and control samples
using unsupervised hierarchical clustering. Most signifi-
cantly, the expression of tDRs in pre-treatment samples
was found to predict response to treatment with DNMTIs.
These tDRs were found to explain 67 % of the variation intreatment response. The expression of these entities could
be used in the clinical setting to select patients likely to re-
spond to DNMTIs. Since only a minority of patients
achieve a clinically meaningful response of hematologic
improvement, partial response, or complete response to
DNMTI therapy, and since it typically takes 3–6 cycles be-
fore a response is evident [48], pre-treatment identifica-
tion of patients likely not to benefit from DNMTI therapy
would enable earlier decisions about stem cell transplant-
ation or investigational therapies in those patients. Using
changes in tDR expression between pre- and post-
treatment samples in model fitting would explain less vari-
ation in the data (R2 = 40 %); however, since pre-treatment
tRNA expression is a more clinically useful analysis, the
better prediction value is fortuitous. Unfortunately, due to
the small size of this study, internal validation methods
have limited utility. The optimal method to demonstrate
the sensitivity and specificity of these biomarkers is to
utilize an independent dataset. This will be the focus of fu-
ture efforts.
Due to the recent developments in the study of mt-
tRNAs and their association with various human diseases
[60], the intriguing studies on mitochondrial aberrations
in MDS [73], and the identification of chrM.tRNA12.TS1
and chrM.tRNA10.TC in our initial analyses, we examined
the expression of mt-tRNA-derived species in MDS. We
identified 22 mt-tDRs which individually are differentially
expressed in MDS compared to control samples, as well
as in responders and non-responders to DNMTI therapy.
Again, these may be valuable diagnostic and prognostic
markers in MDS; however, the correlation between this
functional subset tDRs and the mitochondrial aberrations
seen in MDS is unclear.
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sequences in the MDS samples as compared to the con-
trols. While this may simply point to underlying genomic
instability of myeloid neoplasms, studies in acute myeloid
leukemia have not generally found increased absolute
numbers of mutations [74], and many mutations are
found as a result of aging alone in individuals without any
significant hematolymphoid malignancy [75–77]. There-
fore, there may be real functional consequences of these
SNVs which may affect the functions of these tRNA-
derived species. It should be noted that RNA-seq is not a
well-accepted method for the identification of SNVs due
to the high error rate of the reverse transcription step
and the RNA editing process [78, 79]. In addition, the
presence of numerous modified nucleotides in tRNAs
(e.g. methylation) can result in base errors during the
reverse transcription step of RNA-seq [22]. However,
these SNVs were not identified to an appreciable level in
the control samples, which were processed identically in a
blinded fashion, suggesting that the significance of this
finding is not an artifact.
Study of tRNA fragments using miRNA sequencing
data is not without limitation. As we described previ-
ously, tRNAs are typically 73–94 nucleotides in length,
composed of three hairpin-turns in a cloverleaf two-
dimensional structure. The most 5’ of these loops is the
D loop. Within this loop there is a site that has been
shown to be sensitive to cleavage either by Dicer or by
simple incubation with MgCl2 to afford a 19 nucleotide
product from the 5’ end [10]. However, figures in this
same publication also identify a cleavage product of
greater than 30 nucleotides [10] that is too small to
correspond to the residual 3’ fragment. As we have shown,
33 nucleotide tRNA derivatives were identified by our se-
quencing efforts, resulting from cleavage within the sec-
ond hairpin loop containing the anticodon. Our size
selection step would have excluded most of the 19 nucleo-
tide product. In addition, cleavage in the anti-codon loop
occurs physiologically as a result of cleavage by angiogenin
[18] and may be targeted by other nucleases as well [19].
Lastly, due to the poor reverse transcription of full
length parent tRNAs due to nucleotide modifications,
apparent tDRs may result from incomplete reverse
transcription [23]. Thus, for various biological and
technical reasons, it is possible that under the condi-
tions of this study, the 33 base derivative may be the
predominant 5’ tDR product.
The lack of knowledge of the entire sequence of the
tRNA creates ambiguous tRNA annotation. Many of the
tRNA isotypes have not only the same or similar antico-
dons, but also highly homologous sequences 5’ to the anti-
codon. This creates challenges in the identification of
specific species that may be diagnostically or prognostic-
ally useful. As mentioned in the results, several of theprognostic tRNA fragments are homologous. Therefore,
although the degenerate species are individually identified,
the prognostic power may lie in only one of the entities.
Also, in Table 4, a G >A SNV was identified in five
SerAGA tRNAs. Since the first 33 base pairs of these five
tRNAs are the same, the redundant alignment resulted in
the identification of a G > A SNV in all five SerAGA
tRNAs for the homologous position, when in fact it may
have only been seen in as few as one of the five SerAGA
isotypes. The actual nucleotide sequences of each of the
tDRs specifically mentioned in this study are available for
comparison in Additional file 1: Table S5. Furthermore,
we used VarScan 2 to identify SNVs. Typically, at least
20 % of the reads need to support the alternative allele in
order to be called an SNV by VarScan 2. So, although
none of the control samples in Table 4 contained an SNV
as determined by VarScan 2, there may have been low
levels of reads that did not meet the 20 % threshold for
identification of an SNV.
It is unclear if the expression of tDRs represents the true
expression of the full-length tRNAs themselves, if they are
physiologic by-products whose presence at different levels
suggests differential processing and, therefore, half-lives of
the tRNAs, or if they represent biologically active entities
in themselves. Needless to say, this ambiguity complicates
the further exploration of these results, requiring novel
methods to unravel this unknown biology. Recently, new
approaches to library preparation have emerged, including
the use of demethylases and other strategies to remove
modifications prior to reverse transcription. Moreover, the
use of Group II intron reverse transcriptases, that bind
more tightly than retroviral enzymes to the RNA template,
has been demonstrated to overcome modification barriers
to afford full-length tRNA cDNAs in RNA-seq libraries
[80–83]. These methods may be useful in the future to
distinguish the biological tDRs from those that result from
technical artifact.
The exact mechanism by which tDRs may play a role in
the diagnosis of MDS and prognostication of response to
DNMTIs is unclear. There are multitudinous effects of
global hypomethylation that results from DNMTI therapy.
Some tDRs have been demonstrated to function inde-
pendently as biologically active entities. Lee et al. have
identified small tRNA-derived species, including tRF-
1001, which promotes the G2/M transition [11]. However,
the species identified by Lee et al. are typically 17–26
bases long, smaller than the 33 nucleotide reads identified
in this study. Several reports suggest that 30–35 nu-
cleotide long tRNA-derived fragments may play a role
in the biogenesis of other small RNAs, and these have
been found in wide ranges of species, including humans.
Yamasaki et al. suggest that these fragments may mediate
stress-related translational repression [84]. However, these
explanations would have unclear biologic importance in
Guo et al. BMC Genomics  (2015) 16:727 Page 9 of 11the differential expression of specific tRNA-derived se-
quences. Alterations in the activity of DICER, and hence
of miRNAs, are a common feature in cancers [85–87].
tRNAs have been proposed as alternative DICER1
substrates [39]. Whether certain tRNAs are selectively
targeted by DICER1 in cancer in general, and MDS in par-
ticular, remains to be seen, but it provides an intriguing
hypothesis for the differentially expressed tDRs identified
in this study in association with both the diagnosis and
prognosis of MDS.
Conclusions
This study suggests that tRNA-derived fragment sequen-
cing can provide an additional source of data that poten-
tially provides clinically useful applications in diagnosis
and prognosis of disease. In addition, this study raises
intriguing questions about the biology of these tRNA
derivatives in MDS and other cancers.
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